Bachem (BANB.SW)

Executive Summary

Bachem is a premier Swiss CDMO with over 50 years of expertise in peptides and oligonucleotides, serving as a critical manufacturing partner for the global pharmaceutical industry. The company is leveraged heavily to the booming GLP-1 receptor agonist market, supplying key starting materials and intermediates for blockbuster drugs like semaglutide and tirzepatide. With a strong backlog of commercial-stage contracts and ongoing capacity expansions at its Bubendorf and Vionnaz sites, Bachem is poised to capture sustained revenue growth. However, the firm faces concentration risk from a handful of large customers and pricing pressure as competitors also ramp up peptide manufacturing. Its robust R&D pipeline in oligonucleotides and peptide therapeutics, along with a deep expertise in complex synthesis, underpins a durable competitive advantage. Bachem's financial performance remains solid, with consistent double-digit revenue growth and high operating margins driven by the high-value nature of its services. The company is investing aggressively in new production lines and continuous flow technology to meet surging demand for GLP-1 drugs and emerging oligonucleotide therapies. Looking ahead, Bachem is well-positioned to benefit from the secular shift toward peptide-based medicines, but near-term catalysts hinge on execution of expansion projects and the pace of regulatory approvals for customer programs. The company's proven track record and critical role in the supply chain suggest a stable risk/reward profile, though valuation multiples reflect the premium ascribed to GLP-1 beneficiaries.

Upcoming Catalysts (preview)

• Q3 2026Completion of new GLP-1 API production line at Bubendorf90% success
• Q4 2026Securing of a long-term commercial supply agreement for a novel oligonucleotide therapeutic75% success
• Q1 2027FDA approval of a key customer's late-stage peptide drug reliant on Bachem manufacturing55% success